新天地

301277 SZSE 证监会行业分类 C27医药制造业

Key Metrics

Market Cap

4.6B ($672.0M)

P/E Ratio

N/A

P/B Ratio

N/A

Revenue

672.0M

Net Income

120.0M

Gross Margin

N/A

Op. Margin

20.1%

Net Margin

17.9%

ROE

7.7%

ROA

6.7%

D/E

0.15

Dividend Yield

N/A

EPS

0.31

Current Ratio

6.28

Price History

Company Info

Industry	C27医药制造业
Market Segment	ChiNext
Currency	CNY
Fiscal Year	2025

Business Overview

Full Financials Advanced Charts Filings

Peers

工商银行

601398

2.7T

P/E: 7.6

建设银行

601939

2.5T

P/E: 7.2

农业银行

601288

2.4T

P/E: 8.7

中国海油

600938

2.0T

P/E: 16.2

宁德时代

300750

1.9T

P/E: 25.6

贵州茅台

600519

1.8T

P/E: 20.1

中国银行

601988

1.8T

P/E: 7.3

中国人寿

601628

1.2T

P/E: 6.9

Financial Statements

Loading financials...

Open Advanced Charts

Full charting with technical indicators, candlestick, and more.

About 新天地

Newland Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates and APIs in China. It provides pharmaceutical intermediates, including L-4-hydroxyphenylglycine methyl ester, L-hydroxyphenylglycine potassium salt, L-4-hydroxyphenylglycine, and p-Toluenesulfonic acid. The company also offers APIs, such as ropivacaine hydrochloride, naphazoline hydrochloride, moxifloxacin hydrochloride, lidocaine hydrochloride, vildagliptin, tadalafil, chlorpheniramine maleate, clopidogrel bisulfate, lidocaine, gatifloxacin, febuxostat, esomeprazole sodium, and esomeprazole magnesium. The company was formerly known as Henan Newland Pharmaceutical Co., Ltd. and changed its name to Newland Pharmaceutical Co., Ltd. in June 2023. Newland Pharmaceutical Co., Ltd. was founded in 2005 and is based in Changge, China.

Ticker	301277
Exchange	SZSE
Sector	证监会行业分类
Industry	C27医药制造业